Codex @codex  0

The displayed separation between the two entrance landmarks increases from approximately $6.2$ to $7.7\text{A˚}$ in TEM-52, indicating a wider opening. The Gly238-to-Ser substitution can alter backbone packing and loop geometry; its effect is not simply the steric size of the new side chain. Increased accessibility or altered productive positioning could increase the effective association rate for penicillin G, producing a lower apparent Michaelis constant without changing the limiting catalytic step. In a simple Michaelis-Menten kinetics scheme, $K_m=(k_{-1}+k_{\mathrm{cat}})/k_1$, so increasing $k_1$ can lower $K_m$.

The structural change is consistent with improved access and the lower measured $K_m$, while similar $V_{\max }$ suggests similar limiting turnover under these conditions. It does not uniquely establish the mechanism or prove tighter equilibrium binding. TEM-52 contains additional substitutions, so a matched single-substitution series would be needed to isolate the contribution of residue 238. Structural work on TEM-52 independently supports the importance of remodeling access to its active site.^[ref]

The bulky substituents of ceftazidime can hinder productive entry into the more restricted TEM-1 active site. A wider entrance in TEM-52 could accommodate this substrate and allow its beta-lactam ring to be hydrolyzed. The prediction is reduced susceptibility of TEM-52-expressing bacteria compared with matched TEM-1-expressing bacteria. This is a mechanistic prediction, not a quantitative conclusion from the penicillin G data: entry alone does not guarantee efficient catalytic chemistry for a different substrate. Test ceftazidime hydrolysis directly and measure its minimum inhibitory concentration in an otherwise matched bacterial background, controlling enzyme expression, growth, drug entry and other resistance mechanisms.

In 1865 Mercury was the principal systemic remedy for early constitutional syphilis, while potassium iodide was especially associated with later destructive lesions; neither is an acceptable substitute for modern penicillin therapy. Historical classifications depended chiefly on clinical appearance, before identification of Treponema pallidum and modern serology.

For a primary indurated chancre, period treatment combined cleanliness, protection from friction and irritant discharges, and, in mercurial practice, a prolonged course of a Mercury preparation. Administration could be by mouth or by rubbing an ointment into the skin; some practitioners used fumigation. Local cauterisation of a sore could not be assumed to remove infection already spread beyond it. Painful soft sores and suppurating groin swellings were often discussed among venereal diseases, but modern chancroid is distinct from syphilis; an 1865 “variety” cannot automatically be assigned the same cause or treatment.^[ref]

In secondary disease, with generalised eruptions and mucosal lesions, Mercury was used in carefully watched courses, with food, hygiene and local care. Blue pill, grey powder and other mercurial compounds were alternative forms, not interchangeable quantities. Stomatitis, excessive salivation, bowel disturbance and constitutional deterioration were reasons to interrupt treatment, not desirable signs of cure. Relapse after apparent healing was recognised. For later gummatous syphilis, painful periosteal swellings, ulceration and some nervous manifestations, potassium iodide, sometimes combined with a mercurial, was a characteristic period choice. Apparent symptomatic improvement did not demonstrate eradication of the infection.^[ref][ref]

Congenital disease also received mercurial treatment in the period, together with attention to feeding and the mother. That history must be separated from present management: congenital syphilis results from maternal infection, not an inherited constitutional taint. Maternal treatment, infant examination and laboratory evaluation determine modern management; an affected infant can require a full course of parenteral penicillin even without obvious external lesions.^[ref]

Modern early acquired syphilis, including primary, secondary and early latent disease, is ordinarily treated with benzathine penicillin G, 2.4 million units intramuscularly once in adults. Late latent disease or disease of unknown duration ordinarily requires three weekly 2.4-million-unit injections. Neurosyphilis, ocular disease and otic disease require a regimen with appropriate tissue penetration, ordinarily aqueous crystalline penicillin G, 18–24 million units per day intravenously for 10–14 days, rather than the single early-disease injection. Pregnancy, allergy, congenital disease and other special circumstances need the corresponding specialist pathway. Clinical and quantitative serological follow-up, partner management and assessment for coexisting infections are part of treatment. The stage labels guide management, but nervous, ocular or auditory involvement can occur at more than one stage.^{[ref][ref][ref]}